Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Westwood Holdings Group Inc.

Westwood Holdings Group Inc. lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 64.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 456,712 shares of the biopharmaceutical company’s stock after selling 834,552 shares during the quarter. Westwood Holdings Group Inc.’s holdings in Gilead Sciences were worth $33,454,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Gilead Sciences by 2.6% during the first quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock valued at $8,404,161,000 after purchasing an additional 2,910,147 shares during the last quarter. Capital World Investors lifted its stake in Gilead Sciences by 1.4% during the first quarter. Capital World Investors now owns 84,497,404 shares of the biopharmaceutical company’s stock valued at $6,189,435,000 after purchasing an additional 1,133,281 shares during the last quarter. Capital Research Global Investors lifted its stake in Gilead Sciences by 2.7% during the first quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company’s stock valued at $4,486,296,000 after purchasing an additional 1,589,240 shares during the last quarter. Wellington Management Group LLP lifted its stake in Gilead Sciences by 14.4% during the fourth quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock valued at $1,509,227,000 after purchasing an additional 2,350,550 shares during the last quarter. Finally, Norges Bank acquired a new stake in Gilead Sciences during the fourth quarter valued at approximately $1,301,624,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.4 %

Gilead Sciences stock traded up $0.28 during mid-day trading on Friday, hitting $76.77. 6,458,108 shares of the company’s stock were exchanged, compared to its average volume of 6,392,589. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The stock has a 50 day moving average of $68.80 and a two-hundred day moving average of $70.88. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The stock has a market cap of $95.64 billion, a P/E ratio of 213.25, a P/E/G ratio of 3.37 and a beta of 0.18.

Analyst Ratings Changes

Several analysts recently commented on the stock. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. TD Cowen dropped their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, April 26th. HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research report on Wednesday, April 24th. Oppenheimer reissued an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $74.00 target price on shares of Gilead Sciences in a research report on Monday, July 1st. Twelve investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $81.81.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.